Premium
Relationship between spectral analysis, SUV and SUV Pons ratio as a measure of cerebral glucose metabolic rate in Alzheimer's disease
Author(s) -
Edison Paul,
Raza Sanara,
Femminella Grazia Daniela,
Blunt Eleanor G,
Carver Stefan,
Livingston Nicholas R,
Nowell Joseph,
Holmes Clive,
Ritchie Craig W.,
Lawrence Robert M,
McFarlane Brady,
Tadros George,
Ridha Basil H,
Bannister Carol,
Walker Zuzana,
Archer Hilary,
Coulthard Elizabeth,
Underwood Ben,
Prasanna Aparna,
Koranteng Paul,
Karim Salman,
Junaid Kehinde,
McGuinness Bernadette,
Nilforooshan Ramin,
Macharouthu Ajayverma,
Donaldson Andrew,
Thacker Simon,
Russell Gregor,
Malik Naghma,
Mate Vandana,
Knight Lucy,
Kshemendran Sajeev,
Harrison John E,
Brooks David J,
Passmore Anthony Peter,
Ballard Clive
Publication year - 2020
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.046068
Subject(s) - pons , temporal lobe , nuclear medicine , medicine , standardized uptake value , blood sampling , fluorodeoxyglucose , positron emission tomography , hippocampus , psychiatry , epilepsy
Background Cerebral metabolic rate of glucose (CMRglc) can be measured with fluorodeoxyglucose (FDG) positron emission tomography (PET) using arterial blood sampling. However, blood sampling is an invasive methodology for subjects. Standard uptake value (SUV) is a non‐invasive method to assess the cerebral glucose metabolism. Here we evaluate the relationship between semi‐quantitative measurements such as SUV and Pons ratio with a quantitative measurement such as Spectral analysis (SA) in order to assess their surrogate use in clinical trials. Methods To assess cerebral glucose metabolism by a non‐invasive and simplified method, the standardized uptake value (SUV) and used the Pons RATIO (where target region was divided by pons as a reference region, which requires no arterial input function or blood sampling. The SA was performed using blood sampling to create the input function. The study participants included 63 subjects (mean ± SD age, 71 ± 8 years) from the Evaluating Liraglutide in Alzheimer’s Disease (ELAD) trial. Regional CMRglucose (CMRglc) and regional SUV were measured using FDG PET, and the correlation between CMRglc and SUV together with CMRglc and Pons ratio were estimated for the temporal lobe, medial temporal lobe and hippocampus Results In this AD population, the SA and SUV in the temporal lobe (r=0.635, p= >0.001), medial temporal lobe (0.533, p= >0.001) and hippocampus (r=0.539, p= >0.001) had a positive correlation and were statistically significant. The correlation coefficient between SA and Pons ratio for the temporal lobe (r=0.166, p= 0.194), medial temporal lobe (r=0.146, p=0.146) and the hippocampus (r=0.193, p=0.129) was positive but not statistically significant. Conclusion The SUV correlated better with cerebral glucose metabolic rate using SA than Pons RATIO in AD subjects, while Pons RATIO did not perform well. Therefore, SUV analysis maybe more reliable analysis method compared to Pons RATIO for FDG PET in clinical trials in AD subjects.